Trial Profile
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Lerociclib (Primary) ; Osimertinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors G1 Therapeutics
- 20 Sep 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Dec 2021.
- 22 Jan 2020 Status changed from recruiting to active, no longer recruiting.